Lymphocyte Landscape after Chronic Hepatitis C Virus (HCV) Cure: The New Normal.
Lymphocyte Landscape after Chronic Hepatitis C Virus (HCV) Cure: The New Normal.
复制标题
慢性丙型肝炎病毒（HCV）治疗后的淋巴细胞景观：新正常。
DOI：
10.3390/ijms21207473
复制
发表时间：
2020-10-10
影响因子：
5.6
通讯作者：
Poonia B
中科院分区：
文献类型：
--
作者：
Ghosh A;Romani S;Kottilil S;Poonia B
慢性HCV（CHC）感染是唯一的慢性病毒感染，治愈性治疗已被发现。这些直接作用的抗病毒（DAA）剂靶向病毒复制周期中的特定步骤，具有显著的功效，并导致高比例（>95%）患者的持续病毒学应答（SVR）或治愈。这些治疗在6-7年前就已可用，据估计，它们对HCV相关发病率的真实的影响，包括肝硬化和肝细胞癌（HCC）等结局，在未来十年左右还不清楚。慢性感染患者的免疫系统严重失调，并且关于免疫系统限制治愈个体的肝脏病理的能力的问题仍然存在。用DAA清除HCV的患者免疫力受损的另一个重要后果是无法产生针对可能的再感染的保护性免疫力，需要再治疗或开发预防性疫苗。因此，许多研究小组正在研究病毒清除对恢复免疫稳态的影响。需要回答的重要问题包括：治愈后免疫系统恢复正常的程度如何，病毒清除后多久会发生这种重新校准，持续存在免疫缺陷对保护弱势人群免受再次感染的后果是什么，以及病毒清除是否会降低肝脏病理学和用这些药物治愈的个体发生肝细胞癌的风险。在这里，我们回顾了最近的文献，描述了缺陷存在于各种淋巴细胞群体在CHC患者和他们的状态后，使用DAA治疗病毒清除。
Chronic HCV (CHC) infection is the only chronic viral infection for which curative treatments have been discovered. These direct acting antiviral (DAA) agents target specific steps in the viral replication cycle with remarkable efficacy and result in sustained virologic response (SVR) or cure in high (>95%) proportions of patients. These treatments became available 6–7 years ago and it is estimated that their real impact on HCV related morbidity, including outcomes such as cirrhosis and hepatocellular carcinoma (HCC), will not be known for the next decade or so. The immune system of a chronically infected patient is severely dysregulated and questions remain regarding the immune system’s capacity in limiting liver pathology in a cured individual. Another important consequence of impaired immunity in patients cleared of HCV with DAA will be the inability to generate protective immunity against possible re-infection, necessitating retreatments or developing a prophylactic vaccine. Thus, the impact of viral clearance on restoring immune homeostasis is being investigated by many groups. Among the important questions that need to be answered are how much the immune system normalizes with cure, how long after viral clearance this recalibration occurs, what are the consequences of persisting immune defects for protection from re-infection in vulnerable populations, and does viral clearance reduce liver pathology and the risk of developing hepatocellular carcinoma in individuals cured with these agents. Here, we review the recent literature that describes the defects present in various lymphocyte populations in a CHC patient and their status after viral clearance using DAA treatments.
登录
查看更多内容
影响因子：
64.8
作者：
Bettelli, E;Carrier, YJ;Kuchroo, VK
通讯作者：
Kuchroo, VK
影响因子：
15.9
作者：
Chen, Diana Y.;Wolski, David;Lauer, Georg M.
通讯作者：
Lauer, Georg M.
影响因子：
30.5
作者：
Blackburn, Shawn D.;Shin, Haina;Haining, W. Nicholas;Zou, Tao;Workman, Creg J.;Polley, Antonio;Betts, Michael R.;Freeman, Gordon J.;Vignali, Dario A. A.;Wherry, E. John
通讯作者：
Wherry, E. John
影响因子：
32.4
作者：
Bengsch B;Johnson AL;Kurachi M;Odorizzi PM;Pauken KE;Attanasio J;Stelekati E;McLane LM;Paley MA;Delgoffe GM;Wherry EJ
通讯作者：
Wherry EJ
影响因子：
4.6
作者：
Rios DA;Valva P;Casciato PC;Frias S;Soledad Caldirola M;Gaillard MI;Bezrodnik L;Bandi J;Galdame O;Ameigeiras B;Krasniansky D;Brodersen C;Mullen E;Matteo EN;Preciado MV
通讯作者：
Preciado MV